지속적 신대체요법(CRRT) 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2025-2034년)

Growth Factors of Continuous Renal Replacement Therapy (CRRT) Market

The global Continuous Renal Replacement Therapy (CRRT) market was valued at USD 1.25 billion in 2025 and is projected to reach USD 1.34 billion in 2026, ultimately expanding to USD 2.52 billion by 2034, exhibiting a CAGR of 8.20% during the forecast period. North America dominated the market in 2025 with a 39.72% share, driven by the rising prevalence of acute kidney injury (AKI), advanced healthcare infrastructure, and growing adoption of CRRT in intensive care units (ICUs). Key players include Baxter, Fresenius Medical Care AG & Co. KGaA, and B Braun SE, focusing on technological innovation and product expansion.

CRRT is a specialized form of dialysis designed for critically ill patients with hemodynamic instability and acute kidney injury. Unlike intermittent hemodialysis, CRRT operates continuously over 24 hours, allowing gradual removal of waste, fluids, and electrolytes. This minimizes rapid hemodynamic changes and closely mimics natural kidney function, making it particularly effective for patients with multiple organ failure in ICU settings.

Market Drivers

Increasing ICU Admissions and AKI Prevalence: Globally, the incidence of AKI is rising, particularly among critically ill patients. For instance, the UK Renal Registry reported 683,136 AKI cases in 2023, a 15.8% increase over 2022. Rising ICU admissions due to chronic conditions, sepsis, and COVID-19 complications have further boosted the demand for CRRT, as it provides continuous renal support while maintaining hemodynamic stability.

Technological Advancements: CRRT systems have evolved with enhanced automation, fluid management, and integration of artificial intelligence (AI) for real-time patient monitoring. In May 2021, Baxter launched PrisMax2, offering improved organ support and fluid management, demonstrating how innovation drives market growth.

Pediatric CRRT Devices: The increasing incidence of AKI among pediatric ICU patients presents a new growth opportunity. Specialized CRRT systems for children address unique physiological needs, allowing tailored treatment rather than relying on adult extrapolation. Regulatory approvals, such as the FDA classifying pediatric CRRT devices as Class II in September 2024, facilitate safer adoption.

Market Restraints

High Costs: The high upfront costs of CRRT systems and consumables, estimated at USD 870 per day compared to USD 270 for intermittent hemodialysis, limit adoption in cost-sensitive healthcare settings, particularly in developing regions. Shortage of skilled professionals and the complexity of CRRT setup further restrict widespread implementation.

Market Opportunities

Integration of AI and Home-Based CRRT Solutions: Recent grants and research initiatives, such as the USD 3.8 million U.S. AI grant in June 2023, aim to optimize CRRT outcomes. Portable and home-based CRRT solutions are emerging, expanding market potential beyond hospital ICUs.

Market Segmentation

By Product Type: In 2026, the consumables segment dominated with 73.34% share, driven by repetitive use of filters, dialysates, catheters, and replacement solutions. The systems segment is projected to grow steadily, supported by advanced CRRT devices in developed countries.

By Modality: Continuous Venovenous Hemodiafiltration (CVVHDF) led in 2026 with 45.55% share, due to its effective solute clearance through diffusion and convection. Other modalities, including CVVHD, CVVH, and SCUF, are expected to grow gradually with increasing clinical adoption.

By Region:

• North America: Dominated with USD 0.42 billion in 2025 and USD 0.45 billion in 2026, driven by high AKI prevalence, ICU infrastructure, and adoption of advanced CRRT systems. The U.S. is projected to reach USD 0.49 billion by 2026.
• Europe: Second-largest market with projected USD 0.07 billion (UK) and USD 0.1 billion (Germany) in 2026, supported by rising renal disorders and government focus on renal care.
• Asia Pacific: Fastest-growing region; Japan USD 0.06 billion, China USD 0.08 billion, India USD 0.03 billion in 2026, due to aging populations and high ICU AKI incidence.
• Latin America & Middle East & Africa: Moderate growth fueled by increasing adoption of CRRT in ICU patients and strategic partnerships with global players.

Competitive Landscape

The market is consolidated, with Baxter, Fresenius Medical Care AG & Co. KGaA, and B Braun SE holding substantial shares. Innovations such as B. Braun's acquisition of Intermedt Medizin & Technik GmbH in March 2022 and Baxter's strategic spin-offs demonstrate the focus on expanding CRRT offerings.

Conclusion

The global CRRT market is projected to expand steadily from USD 1.25 billion in 2025 to USD 2.52 billion by 2034, driven by increasing AKI prevalence, rising ICU admissions, technological innovations, and expanding pediatric and home-based CRRT solutions. North America continues to dominate, while Asia Pacific offers the fastest growth. Consumables and CVVHDF modalities lead the market. Strategic product development and adoption of AI-integrated and user-friendly CRRT systems will further enhance patient outcomes and global market expansion.

Segmentation By Product Type

• Systems
• Consumables
  • Dialysates
  • Replacement Solutions
  • Filters
  • Catheters
  • Others

By Modality

• Slow Continuous Ultra Filtration (SCUF)
• Continuous Venovenous Hemofiltration (CVVH)
• Continuous Venovenous Hemodialysis (CVVHD)
• Continuous Venovenous Hemodiafiltration (CVVHDF)

By Region

• North America (By Product Type, By Modality, By Country)
  • U.S.
  • Canada
• Europe (By Product Type, By Modality, By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, By Modality, By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, By Modality, By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, By Modality, By Country/Sub-Region)
  • South Africa
  • GCC
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Epidemiology of Acute Kidney Failure by Key Countries, 2025
• 4.2. Reimbursement Scenario for Key Countries/Regions
• 4.3. New Product Launches, Key Players
• 4.4. Key Industry Developments Mergers, Acquisitions, and Partnerships
• 4.5. Impact of Covid-19 on the Market

5. Global Continuous Renal Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Systems
  • 5.1.2. Consumables
    • 5.1.2.1. Dialysates
    • 5.1.2.2. Replacement Solutions
    • 5.1.2.3. Filters (Hemofilters, Plasmafilters, etc.)
    • 5.1.2.4. Catheters
    • 5.1.2.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Modality
  • 5.2.1. Slow Continuous Ultra Filtration (SCUF)
  • 5.2.2. Continuous Venovenous Hemofiltration (CVVH)
  • 5.2.3. Continuous Venovenous Hemodialysis (CVVHD)
  • 5.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Continuous Renal Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Systems
  • 6.1.2. Consumables
    • 6.1.2.1. Dialysates
    • 6.1.2.2. Replacement Solutions
    • 6.1.2.3. Filters (Hemofilters, Plasmafilters, etc.)
    • 6.1.2.4. Catheters
    • 6.1.2.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Modality
  • 6.2.1. Slow Continuous Ultra Filtration (SCUF)
  • 6.2.2. Continuous Venovenous Hemofiltration (CVVH)
  • 6.2.3. Continuous Venovenous Hemodialysis (CVVHD)
  • 6.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Continuous Renal Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Systems
  • 7.1.2. Consumables
    • 7.1.2.1. Dialysates
    • 7.1.2.2. Replacement Solutions
    • 7.1.2.3. Filters (Hemofilters, Plasmafilters, etc.)
    • 7.1.2.4. Catheters
    • 7.1.2.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Modality
  • 7.2.1. Slow Continuous Ultra Filtration (SCUF)
  • 7.2.2. Continuous Venovenous Hemofiltration (CVVH)
  • 7.2.3. Continuous Venovenous Hemodialysis (CVVHD)
  • 7.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Continuous Renal Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Systems
  • 8.1.2. Consumables
    • 8.1.2.1. Dialysates
    • 8.1.2.2. Replacement Solutions
    • 8.1.2.3. Filters (Hemofilters, Plasmafilters, etc.)
    • 8.1.2.4. Catheters
    • 8.1.2.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Modality
  • 8.2.1. Slow Continuous Ultra Filtration (SCUF)
  • 8.2.2. Continuous Venovenous Hemofiltration (CVVH)
  • 8.2.3. Continuous Venovenous Hemodialysis (CVVHD)
  • 8.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Continuous Renal Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Systems
  • 9.1.2. Consumables
    • 9.1.2.1. Dialysates
    • 9.1.2.2. Replacement Solutions
    • 9.1.2.3. Filters (Hemofilters, Plasmafilters, etc.)
    • 9.1.2.4. Catheters
    • 9.1.2.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Modality
  • 9.2.1. Slow Continuous Ultra Filtration (SCUF)
  • 9.2.2. Continuous Venovenous Hemofiltration (CVVH)
  • 9.2.3. Continuous Venovenous Hemodialysis (CVVHD)
  • 9.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Continuous Renal Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Systems
  • 10.1.2. Consumables
    • 10.1.2.1. Dialysates
    • 10.1.2.2. Replacement Solutions
    • 10.1.2.3. Filters (Hemofilters, Plasmafilters, etc.)
    • 10.1.2.4. Catheters
    • 10.1.2.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Modality
  • 10.2.1. Slow Continuous Ultra Filtration (SCUF)
  • 10.2.2. Continuous Venovenous Hemofiltration (CVVH)
  • 10.2.3. Continuous Venovenous Hemodialysis (CVVHD)
  • 10.2.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. South Africa
  • 10.3.2. GCC
  • 10.3.3. Rest of Middle East Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Baxter
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. B. Braun SE
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Fresenius Medical Care AG & Co. KGaA
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Asahi Kasei Medical Co., Ltd. (Asahi Kasei Corporation)
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. NIPRO Corporation
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Toray Medical Co., Ltd (TORAY INDUSTRIES, INC.)
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Nikkiso Co., Ltd.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Medtronic
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)